Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intravenous oxytocin

Phase 2

WWake Forest University Health Sciences

Intravenous oxytocin is one of 2 therapeutic programs targeting Pain, Acute. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pain, AcuteCompleted

Pain, AcutePhase 2

Completed

Competition

Competitive Landscape

3 competitors in Pain, Acute

#DrugCompanyPhaseTrials

Intranasal Oxytocin

UUniversity of Electronic Science and Technology of China

Intravenous oxytocin

WWake Forest University Health Sciences

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pain, Acute1 trial

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Completed·WWake Forest University Health Sciences·Phase 2·NCT07053774·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous oxytocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intravenous oxytocin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: WWake Forest University Health Sciences

Related News